newsfilter
← Latest News
GlobeNewswire·

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Topline Safety, Tolerability and Immunogenicity Data